Can the mirtazapine dose be increased to 15 mg nightly from 7.5 mg after two days, given the patient’s improving renal function (estimated glomerular filtration rate ≈ 35 mL/min/1.73 m², serum creatinine ≈ 1.6 mg/dL)?

Can Mirtazapine Be Increased to 15 mg from 7.5 mg After Two Days?

Yes, you can increase mirtazapine to 15 mg nightly after two days, even with an eGFR of 35 mL/min/1.73 m², but proceed with heightened monitoring for sedation and other adverse effects given the moderate renal impairment.

Rationale Based on FDA Labeling and Pharmacokinetics

The FDA-approved starting dose of mirtazapine is 15 mg once daily at bedtime 1. The 7.5 mg starting dose used in this patient represents a conservative, off-label approach—likely chosen due to renal impairment concerns. However, the FDA label explicitly states that dose changes should not be made in intervals less than 1 to 2 weeks 1. Your proposed increase at day 2 is earlier than recommended.

Renal Impairment Considerations

Mirtazapine clearance is significantly reduced in renal dysfunction:

• Patients with eGFR 11-39 mL/min/1.73 m² (which includes your patient at eGFR ~35) show approximately 30% reduction in total body clearance 1
• Those with eGFR <10 mL/min/1.73 m² have approximately 50% reduction 1
• The drug is 75% renally eliminated 1

The FDA label recommends dosage decrease may be necessary in moderate to severe renal impairment 1. However, it does not provide specific dosing adjustments, leaving clinical judgment paramount.

Practical Dosing Strategy

Given the improving renal function (eGFR 35, creatinine 1.64 mg/dL):

1. The 15 mg dose is reasonable as it represents the standard FDA-approved starting dose 1

2. The two-day interval is premature based on FDA guidance, but may be acceptable if:

   • The patient experienced no adverse effects at 7.5 mg
   • There is clinical urgency for symptom control
   • Close monitoring for sedation, confusion, and orthostatic hypotension is feasible

3. Optimal approach: Wait 5-7 days at 7.5 mg before advancing to 15 mg, consistent with general antidepressant titration principles 2 and allowing assessment of tolerability in the context of reduced clearance

Monitoring Parameters

Watch closely for:

• Excessive sedation/somnolence (most common adverse effect, occurring in 23% vs 14% placebo) 1
• Confusion or over-sedation (elderly and renally impaired patients are at higher risk) 1
• Orthostatic hypotension
• Weight gain and increased appetite (11% vs 2% placebo) 1

Pharmacokinetic Context

• Mirtazapine has a half-life of 20-40 hours 1, meaning steady-state is reached in approximately 4-8 days
• Females exhibit significantly longer elimination half-lives (37 hours vs 26 hours in males) 1—if your patient is female, this further supports slower titration
• Plasma concentrations show high interindividual variability; therapeutic levels are typically 30-130 ng/mL 3, with a threshold of 30 ng/mL for response 4

Clinical Bottom Line

While 15 mg is the standard starting dose and appropriate for this level of renal function, advancing at day 2 is faster than recommended. If clinical circumstances demand rapid titration, proceed to 15 mg with intensive monitoring. Otherwise, wait 5-7 days to better assess tolerability and allow partial approach to steady-state at the lower dose. The improving renal function is reassuring, but the 30% reduction in clearance at eGFR 35 means this patient will have higher drug exposure than someone with normal renal function 1.